Resveratrol and endometrium: A closer look at an active ingredient of red wine using in vivo and in vitro models

Reproductive Sciences

Volumn 21, Issue 11, 2014, Pages 1362-1369

  Amaya, S C ^a   Savaris, R F ^b,d   Filipovic, C J ^a   Wise, J D ^a,c   Hestermann, E ^a,c   Young, S L ^d   Lessey, B A ^a  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FURMAN UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cell proliferation; Endometriosis; Estrogen receptor; Human endometrium; Ishikawa; Resveratrol

Indexed keywords

ALKALINE PHOSPHATASE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTROGEN; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; PROGESTERONE; RESVERATROL; AHR PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CYP1A1 PROTEIN, HUMAN; CYP1B1 PROTEIN, HUMAN; DIETHYLSTILBESTROL; DNA BINDING PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA, HUMAN; PHYTOESTROGEN; RAG2 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENZYME ANALYSIS; ESTROGEN ACTIVITY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PELVIS PAIN SYNDROME; PROTEIN EXPRESSION; RED WINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; KNOCKOUT MOUSE; METABOLISM; OVARIECTOMY; TIME; TRANSPLANTATION; WINE; XENOGRAFT;

ALKALINE PHOSPHATASE; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1B1; DIETHYLSTILBESTROL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIUM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HETEROGRAFTS; HUMANS; KI-67 ANTIGEN; MICE, INBRED C57BL; MICE, KNOCKOUT; OVARIECTOMY; PHYTOESTROGENS; RECEPTORS, ARYL HYDROCARBON; STILBENES; TIME FACTORS; WINE;

EID: 84909592401     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114525271     Document Type: Article

References (50)

1. Kinghorn AD, Su BN, Jang DS, et al. Natural inhibitors of carcinogenesis. Planta Med. 2004;70(8):691-705.
2. Jiang H, Shang X, Wu H, et al. Resveratrol downregulates PI3K/ Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol. 2009;8(1):25-33.
3. Sun C, Hu Y, Liu X, et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet. 2006;165(1):9-19.
4. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann N Y Acad Sci. 2007;1095:441-448.
5. Vanamala J, Radhakrishnan S, Reddivari L, Bhat VB, Ptitsyn A. Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach. Proteome Sci. 2011;9(1):49.
6. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod. 2011;84(1):106-112.
7. Maia HJ, Haddad C, Pinheiro N, Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health. 2012; 4:543-549.
8. Ricci AG, Olivares CN, Bilotas MA, et al. Natural therapies assessment for the treatment of endometriosis. Hum Reprod. 2013;28(1):178-188.
9. Singh M, Parent S, Leblanc V, Asselin E. Resveratrol modulates the expression of PTGS2 and cellular proliferation in the normal rat endometrium in an AKT-dependent manner. Biol Reprod. 2011;84(5):1045-1052.
10. Shirane A, Wada-Hiraike O, Tanikawa M, et al. Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression. Biochem Biophys Res Commun. 2012;424(3):604-610.
11. Rier S, Foster WG. Environmental dioxins and endometriosis. Toxicol Sci. 2002;70(2):161-170.
12. Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol. 2011;127(3-5):204-215.
13. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. 2013;28(11):1552-1568.
14. Janssen EB, Rijkers AC, Hoppenbrouwers K, Meuleman C, D'Hooghe TM. Prevalence of endometriosis diagnosed by laparoscopy in adolescents with dysmenorrhea or chronic pelvic pain: a systematic review. Hum Reprod Update. 2013;19(5):570-582.
15. Burney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148(8):3814-3826.
16. Young SL, Lessey BA. Progesterone function in human endometrium: clinical perspectives. Semin Reprod Med. 2010;28(1):5-16.
17. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA. Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4(suppl 1):S9.
18. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci. 2002;955:75-85.
19. Igarashi TM, Bruner-Tran KL, Yeaman GR, et al. Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fertil Steril. 2005;84(1):67-74.
20. Bulun SE, Cheng YH, Yin P, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248(1-2):94-103.
21. Fazleabas AT, Brudney A, Chai D, Langoi D, Bulun SE. Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil Steril. 2003;80(suppl 2):820-827.
22. Bulun SE, Cheng YH, Pavone ME, et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med. 2010;28(1):36-43.
23. Casper RF, Quesne M, Rogers IM, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol. 1999;56(4): 784-790.
24. Bhat KP, Pezzuto JM. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res . 2001;61(16):6137-6144.
25. Greenberg LH, Slayden OD. Human endometriotic xenografts in immunodeficient RAG-2/gamma(c)KO mice. Am J Obstet Gynecol. 2004;190(6):1788-1795.
26. Littlefield BA, Gurpide E, Markiewicz L, McKinley B, Hochberg RB. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. Endocrinology. 1990;127(6):2757-2762.
27. Mo B, Vendrov AE, Palomino WA, DuPont BR, Apparao KB, Lessey BA. ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol Reprod. 2006;75(3):387-394.
28. Lovely LP, Appa Rao KB, Gui Y, Lessey BA. Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem Mol Biol. 2000;74(4):235-241.
29. Collins NH, Lessey EC, DuSell CD, et al. Characterization of antiestrogenic activity of the Chinese herb, prunella vulgaris, using in vitro and in vivo (Mouse Xenograft) models. Biol Reprod. 2009;80(2):375-383.
30. Budwit-Novotny DA, McCarty KS, Cox EB, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986;46(10): 5419-5425.
31. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-1108.
32. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227(2):115-124.
33. Chen ZH, Hurh YJ, Na HK, et al. Resveratrol inhibits TCDDinduced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis. 2004;25(10): 2005-2013.
34. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141(10):3657-3667.
35. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol . 1999;179(3):297-304.
36. Kang NH, Hwang KA, Lee HR, Choi DW, Choi KC. Resveratrol regulates the cell viability promoted by 17beta-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor alpha and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Food Chem Toxicol. 2013;59:373-379.
37. Macpherson L, Matthews J. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor alpha expression in human breast cancer cells. Cancer Lett. 2010;299(2):119-129.
38. Dong WH, Chen JC, He YL, Xu JJ, Mei YA. Resveratrol inhibits Kv2.2 currents through the estrogen receptor GPR30- mediated PKC pathway. Am J Physiol Cell Physiol. 2013; 305(5):C547-C557.
39. Gashaw I, Hastings JM, Jackson KS, Winterhager E, Fazleabas AT. Induced endometriosis in the baboon (Papio anubis) increases the expression of the proangiogenic factor CYR61 (CCN1) in eutopic and ectopic endometria. Biol Reprod. 2006;74(6): 1060-1066.
40. Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44(5):684-694.
41. Isaacson KB, Xu Q, Lyttle CR. The effect of estradiol on the production and secretion of complement component 3 by the rat uterus and surgically induced endometriotic tissue. Fertil Steril. 1991;55(2):395-402.
42. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003;88(6):2889-2899.
43. Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med. 2012;30(1): 39-45.
44. Trukhacheva E, Lin Z, Reierstad S, Cheng YH, Milad M, Bulun SE. Estrogen receptor (ER) beta regulates ERalpha expression in stromal cells derived from ovarian endometriosis. J Clin Endocrinol Metab. 2009;94(2):615-622.
45. Saleh MC, Connell BJ, Saleh TM. Resveratrol induced neuroprotection is mediated via both estrogen receptor subtypes, ER(alpha) and ER(beta). Neurosci Lett. 2013;548:217-221.
46. Robb EL, Stuart JA. Resveratrol interacts with estrogen receptor-beta to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial superoxide dismutase. Free Radic Biol Med. 2011;50(7):821-831.
47. Howells LM, Berry DP, Elliott PJ, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) . 2011;4(9): 1419-1425.
48. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(suppl 1): S7-S15.
49. Amiot MJ, Romier B, Dao TM, et al. Optimization of trans- Resveratrol bioavailability for human therapy. Biochimie. 2013; 95(6):1233-1238.
50. Johnson JJ, Nihal M, Siddiqui IA, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55(8):1169-1176.